Thermo Fisher Scientific H1N1 HA Polyclonal Antibody

Applications

Tested Dilution

Publications

Western Blot (WB)

0.5-1 µg/mL

-

Miscellaneous PubMed (Misc)

-

View 3 publications 3 publications

Product Specifications

Published species

Not Applicable

Host/Isotype

Rabbit / IgG

Class

Polyclonal

Type

Antibody

Immunogen

KLH-coupled synthetic peptide within residues 200-250 of Influenza A (H1N1) 2009 virus HA protein (GenBank: CY039999).

Conjugate

Unconjugated Unconjugated Unconjugated

Form

Lyophilized

Storage conditions

-20°C or -80°C if preferred

Shipping conditions

Wet ice

Product Specific Information

Reconstitute the lyophilized powder with deionized water (or equivalent) to an antibody concentration of 0.5 mg/ml.

Influenza A (H1N1) virus is a subtype of influenzavirus A and the most common cause of influenza (flu) in humans. A strain of swine-origin H1N1 was responsible for the 2009 flu pandemic. HA (Hemagglutinin) is an antigenic glycoprotein found on the surface of the H1N1 virus. And it is responsible for binding the virus to the cell that is being infected.GenScript H1N1 HA Antibody is developed in rabbit using a KLH-coupled synthetic peptide within residues 200-250 of Influenza A (H1N1) 2009 virus HA protein (GenBank: CY039999).

Target Information

Influenza A virus is a major public health threat, killing more than 30,000 people per year in the USA. In early 2009, a novel swine-origin influenza A (H1N1) virus was identified in specimens obtained from patients in Mexico and the United States. The virus spread quickly around the world and on June 11, 2009, the World Health Organization declared it a pandemic. Influenza A virus has one of sixteen possible Hemagglutinin (HA) surface proteins and one of nine possible Neuraminidase (NA) surface proteins. The Hemagglutinin protein facilitates viral attachment while Neuraminidase is involved in viral release. These proteins also elicit immune responses that prevent infection or independently reduce viral replication. The genetic make-up of this swine flu virus is unlike any other: it is an H1N1 strain that combines a triple assortment first identified in 1998 including human, swine, and avian influenza with two new pig H3N2 virus genes from Eurasia, themselves of recent human origin. The distinct antigenic properties of the new swine influenza virus compared with seasonal influenza A (H1N1) virus suggest that human immunity against new swine influenza virus is limited, although the age distribution of reported cases suggests some degree of protection in older age groups.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.